Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07549516 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
MinorTrial sites expanded: 65 → 69 locationsEligibility criteria expanded, about 16 words · Secondary endpoints: details revised at 7 of 19 entriesShow 2 more changesShow less
Eligibility criteria expanded, about 16 words
Secondary endpoints: details revised at 7 of 19 entries
MinorTrial sites expanded: 57 → 65 locationsv7
MinorTrial sites expanded: 54 → 57 locationsEligibility criteria expanded, about 153 words · Secondary endpoints: 18 to 19v6Show 2 more changesShow less
NotableRecruitment openedTrial sites expanded: 0 → 15 locationsv2Show 1 more changeShow less
Trial sites expanded: 0 → 15 locations
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to assess the real-world effectiveness of asciminib in Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP) patients who were either newly diagnosed or previously treated with one ATP-competitive tyrosine kinase inhibitor (TKI).